Erlotinib HCl APIs from Loncom Pharma are instrumental in crafting treatments for non-small cell lung cancer and pancreatic cancer. By inhibiting the epidermal growth factor receptor tyrosine kinase, these APIs effectively block the growth of cancer cells, contributing to improved patient outcomes.
